



ABSTRACT OF THE DISCLOSURE

This invention comprises novel pharmaceutical carrier or excipient systems and oral

- 5 pharmaceutical formulations comprising as an active ingredient raloxifene, amoxifen, droloxi芬e, arzoxifene, or CP 336156, or analogs thereof, or a compound of the formulae I or II:




- 10 wherein Z is a moiety selected from the group of:



wherein: R₁ is selected from H, OH or the C₁-C₁₂ esters alkyl ethers thereof, benzyloxy, or halogen; or C₁-C₄ halogenated ethers; R₂, R₃, R₄, R₅, and R₆ are H, OH or C₁-C₁₂ esters or alkyl ethers thereof, halogens, or C₁-C₄ halogenated ethers, cyano, C₁-C₆ alkyl, or CF₃, with

- 15 the proviso that, when R₁ is H, R₂ is not OH; Y is the moiety:



R₇ and R₈ are alkyl or concatenated together to form an optionally substituted, nitrogen-containing ring; or a pharmaceutically acceptable salt thereof; and excipients chosen from pharmaceutical fillers, glidants, lubricants, wetting agents and antioxidants.